Influenza virus H9N2 vaccine - Crucell

Drug Profile

Influenza virus H9N2 vaccine - Crucell

Latest Information Update: 03 Dec 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Crucell
  • Class Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Influenza A virus H9N2 subtype

Most Recent Events

  • 03 Dec 2012 Janssen licenses the NanoPass MicronJet®, microneedle delivery device for use in its vaccine programmes
  • 14 Aug 2007 Crucell completes a phase I/II trial in the UK
  • 31 May 2006 Phase-I/II clinical trials in Influenza virus infections in United Kingdom (IM, Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top